R&D and Innovation in Sustainable Chemistry
Our journey so far..
Formative years with focus on APIs
Global footprint, Established dominance in
Core APIs + PFls, Entered Finished
dosages space
Expanding into complex generics +
Strengthening market penetration
in regulated markets
Moving towards complex
technology
1984
1990 1991 1993
1995
2001
2002 2003
2005
2008 2010
2013
2014
2014 2015 2016 2019
2021
2022 2022
2023
Established
first PFI
facility at
Listed on
the BSE
Incorporated
Jeedimetla
Entered the
Finished dosage
segment
Acquired API
manufacturing
facility in Vizag to
further strengthen
the API portfolio
Granules India
Private Limited
Opened 2nd API
facility in
Merger of Triton
with Granules
New Paracetamol
plant at
Bonthapally
Established
15,000 sqft R&D
facility in
Jeedimetla
Listed on the
Hyderabad Stock
Exchange
Hyderabad
Received USFDA
Granules formed as Triton
Labs to produce
Paracetamol API at
Bonthapally
Set up a large-volume
PFI facility in Gagillapur
and a wholly owned
subsidiary Granules
-
USA for marketing in
the US
Laid down the
foundation for its
Oncology API and
OSD Plant in Vizag
Acquired Sajjla
Bio Labs to
augment
Biotechnology R&D
Setup GPAK, a
79,000 sqft
packaging facility
in the US
Entered OTC business in US
through Granules Consumer
Healthcare
Setup the largest single
manufacturing site for
MUPS facility
approval for its
first ANDA
Incorporated Granules
Pharmaceutical Inc in the US
to focus on formulations in
the US
Commenced sale of Rx
Products in the US
under the GPI Label
Completed share buy-
back worth Rs.311 Cr
(including taxes and
transaction cost)
4
4View entire presentation